Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=67 Liver Cancer Community Education
Liver Cancer
Primary: Change in Mean Liver Cancer Knowledge — 1.26 score on a scale
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Phase 2 N=11 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Number of Subjects Experiencing Adverse Events — 2 participants
Phase 2 N=19 A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Dose Limiting Toxicity — 0; 0; 0 Participants
Phase 2 N=50 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
Phase 2 N=110 Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
Adult Primary Liver Cancer · Hepatitis C Infection
Primary: Change in Serum AFP Levels — -1.928; 5.855 ng/mL — p=0.160
Phase 2 N=163 CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Advanced Hepatocellular Carcinoma · Liver Cancer · Hepatic Cancer
Primary: Time to Progression (TTP) Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer — 2.8; 3.0; 3.9 months
Phase 2 N=25 Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
Cirrhosis · Hepatocellular Carcinoma
Primary: Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining) — 3; 3; 6 Participants
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 2 N=137 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)
Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants
Phase 2 N=28 Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
Liver Cancer
Primary: Disease Response Rate — 12.5 percentage of participants with response
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants
Phase 2 N=11 TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Hepatocellular Carcinoma · Hepatocellular Cancer · Carcinoma, Hepatocellular
Primary: Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC). — 12 Weeks
Phase 2 N=22 Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Liver Cancer
Primary: Median Overall Survival — 31.1 months
Phase 2 N=37 Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Advanced Adult Hepatocellular Carcinoma · Child-Pugh Class A · Stage III Hepatocellular Carcinoma
Primary: Overall Response Rate Defined as Partial or Complete Response Per Immune-related Response Evaluation Criteria in Solid Tumors — 8; 19 Participants
Phase 2 N=16 Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
Stage III Hepatocellular Carcinoma AJCC v8 · Stage IIIA Hepatocellular Carcinoma AJCC v8 · Stage IIIB Hepatocellular Carcinoma AJCC v7
Primary: Maximum Tolerated Dose (MTD) (Part 1 Only) — 400 milligrams (mg) once per day
Phase 2 N=42 Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST) — 3 percentage of participants
N/A N=300 Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta
Liver Cancer
Primary: Serum Aflatoxin Level in Liver Cancer Patients — 7.96; 6.10; 4.13 ng\ml
Phase 2 N=76 A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma · Liver Cancer
Primary: Tumor Response — 0; 7; 47; 11 Participants
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
N/A N=84 Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Hepatocellular Carcinoma · HCC
Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s
Phase 3 N=235 Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Hepatocellular Carcinoma · Unresectable Hepatocellular Carcinoma
Primary: Progression-free Survival (PFS) — 9.3; 8.4 months — p=0.4
Phase 2 N=30 Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Liver Cancer
Primary: Neovessel Formation as Measured by Angiogram at 14 Weeks — 2; 3 participants
Phase 2 N=24 Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Liver Cancer
Primary: Maximum Tolerated Dose (Phase I) — 2; 3; 0; 0 Participants
Phase 2 N=27 Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR). — 0; 1 participants
Phase 3 N=356 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Advanced Adult Hepatocellular Carcinoma · Recurrent Hepatocellular Carcinoma · Stage III Hepatocellular Carcinoma AJCC v7
Primary: Overall Survival — 8.9; 10.5 month — p=0.24
Phase 2 N=60 Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular Carcinoma
Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001
Phase 2 N=61 Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Heptocellular Cancer · Biliary Tract Neoplasms · Liver Cancer
Primary: Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution — 8; 12; 12; 9 Participants